Market open
Cardiol Therapeutics/$CRDL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Ticker
$CRDL
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Oakville, Canada
Employees
-
Website
CRDL Metrics
BasicAdvanced
$119M
-
-$0.37
0.59
-
Price and volume
Market cap
$119M
Beta
0.59
52-week high
$3.12
52-week low
$0.96
Average daily volume
322K
Financial strength
Current ratio
2.485
Quick ratio
2.323
Long term debt to equity
1.286
Total debt to equity
1.591
Management effectiveness
Return on assets (TTM)
-79.07%
Return on equity (TTM)
-159.53%
Valuation
Price to book
14.13
Price to tangible book (TTM)
14.13
Price to free cash flow (TTM)
-5.467
Growth
Earnings per share change (TTM)
22.12%
3-year earnings per share growth (CAGR)
-16.91%
What the Analysts think about CRDL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cardiol Therapeutics stock.
CRDL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRDL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRDL News
AllArticlesVideos
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
GlobeNewsWire·1 month ago
3 Penny Stocks Ready to Break Out in 2025
MarketBeat·2 months ago
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy
Proactive Investors·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cardiol Therapeutics stock?
Cardiol Therapeutics (CRDL) has a market cap of $119M as of January 27, 2025.
What is the P/E ratio for Cardiol Therapeutics stock?
The price to earnings (P/E) ratio for Cardiol Therapeutics (CRDL) stock is 0 as of January 27, 2025.
Does Cardiol Therapeutics stock pay dividends?
No, Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders as of January 27, 2025.
When is the next Cardiol Therapeutics dividend payment date?
Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.